Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Ernexa Therapeutics Inc. (ERNA)
Company Research
Source: GlobeNewswire
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in-human study planned for Q4 2026 for the treatment of platinum-resistant ovarian cancer Multiple regulatory and clinical milestones expected to drive significant value creation over the next 12-18 months CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today provided a business update highlighting the Company’s accelerating transition toward clinical development and a series of upcoming milestones expected to serve as key value-inflection points over the next 12-18 months. Following significant scientific, regulatory and operational progress, Ernexa is entering a pivotal execution phase as it advances its lead progra
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Ernexa Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series [Yahoo! Finance]Yahoo! Finance
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesGlobeNewswire
- Ernexa Therapeutics Announces Pricing of $10.5 Million Public OfferingGlobeNewswire
- Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDAGlobeNewswire
- Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration ProgramGlobeNewswire
ERNA
Sec Filings
- 4/13/26 - Form DEF
- 4/1/26 - Form PRE
- 3/31/26 - Form EFFECT
- ERNA's page on the SEC website